Analyze the immune pathway, including low-expressing genes, from clinical research samples with as little as 10 ng FFPE RNA
The Oncomine™ Immune Response Research Assay is a targeted, next-generation sequencing (NGS) gene expression assay that enables immuno-oncology research through the quantitative evaluation of the expression of markers associated with different leukocyte subsets, antigen presentation, checkpoint pathways, and tumor progression. The assay measures the expression of genes involved in tumor-immune interactions, including the low-expressing genes involved in inflammatory signaling.